Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

Supplementary Dataset S9 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition

<p>Supplementary Dataset S9</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Cara Abecunas (14960274) (author)
مؤلفون آخرون:	Christopher E. Whitehead (14960277) (author), Elizabeth K. Ziemke (14960280) (author), Douglas G. Baumann (14960283) (author), Christy L. Frankowski-McGregor (14960286) (author), Judith S. Sebolt-Leopold (14960289) (author), Mohammad Fallahi-Sichani (14960292) (author)
منشور في:	2025
الموضوعات:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Drug Targets Skin Cancers Melanoma Small Molecule Agents Kinase inhibitors Systems Biology
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Supplementary Dataset S1 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S2 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S3 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S4 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S5 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S6 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S7 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Dataset S8 from Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition
حسب: Cara Abecunas (14960274)
منشور في: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
حسب: James S. Wilmott (15008931)
منشور في: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
حسب: James S. Wilmott (15008931)
منشور في: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
حسب: Ossia M. Eichhoff (14964145)
منشور في: (2025)

Inhibition of Polo-like kinase 1 (PLK1) synergizes with Vemurafenib in the treatment of melanoma.
حسب: Fengyi Mao (15073242)
منشور في: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
حسب: Jitske van den Bulk (17142147)
منشور في: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
حسب: Jitske van den Bulk (17142147)
منشور في: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
حسب: Jitske van den Bulk (17142147)
منشور في: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
حسب: Jitske van den Bulk (17142147)
منشور في: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
حسب: Jitske van den Bulk (17142147)
منشور في: (2025)

Polo-like kinase 1 (PLK1) is involved in melanoma progression.
حسب: Fengyi Mao (15073242)
منشور في: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
حسب: Caroline Robert (15032672)
منشور في: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
حسب: Caroline Robert (15032672)
منشور في: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
حسب: Caroline Robert (15032672)
منشور في: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
حسب: Caroline Robert (15032672)
منشور في: (2025)

Polo-like kinase 1 (PLK1) induces Vemurafenib resistance in melanoma.
حسب: Fengyi Mao (15073242)
منشور في: (2025)

Supplementary Table 1 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
حسب: Nneoma Adaku (16991063)
منشور في: (2025)

Supplementary Table 2 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
حسب: Nneoma Adaku (16991063)
منشور في: (2025)

Supplementary Table 3 from Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis
حسب: Nneoma Adaku (16991063)
منشور في: (2025)

Overexpressed Polo-like kinase 1 (PLK1) promotes metastasis and metabolic reprogramming in melanoma.
حسب: Fengyi Mao (15073242)
منشور في: (2025)

Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S7 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Table 3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Table 4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Table 5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
حسب: Andrew W. Hahn (15024693)
منشور في: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
حسب: Alexander N. Shoushtari (15023909)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_d34n3a02m759pb99hrkql6uees